{"id":"https://openalex.org/W4313254255","doi":"https://doi.org/10.1016/j.jcf.2022.12.006","title":"Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial","display_name":"Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trial","publication_year":2022,"publication_date":"2022-12-27","ids":{"openalex":"https://openalex.org/W4313254255","doi":"https://doi.org/10.1016/j.jcf.2022.12.006","pmid":"https://pubmed.ncbi.nlm.nih.gov/36581484"},"language":"en","primary_location":{"id":"doi:10.1016/j.jcf.2022.12.006","doi":"https://doi.org/10.1016/j.jcf.2022.12.006","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jcf.2022.12.006","pdf_url":null,"source":{"id":"https://openalex.org/S147774598","display_name":"Journal of Cystic Fibrosis","issn_l":"1569-1993","issn":["1569-1993","1873-5010"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Cystic Fibrosis","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://doi.org/10.1016/j.jcf.2022.12.006","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5005915390","display_name":"Patrick A. Flume","orcid":"https://orcid.org/0000-0002-1560-6879","observed_orcids":["https://orcid.org/0000-0002-1560-6879"]},"institutions":[{"id":"https://openalex.org/I153297377","display_name":"Medical University of South Carolina","ror":"https://ror.org/012jban78","country_code":"US","type":"education","lineage":["https://openalex.org/I153297377"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Patrick A. Flume","raw_affiliation_strings":["MUSC Health Cystic Fibrosis Center, Medical University of South Carolina, 96 Jonathan Lucas St., Charleston, SC, USA. Electronic address: flumepa@musc.edu","MUSC Health Cystic Fibrosis Center, Medical University of South Carolina, 96 Jonathan Lucas St., Charleston, SC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MUSC Health Cystic Fibrosis Center, Medical University of South Carolina, 96 Jonathan Lucas St., Charleston, SC, USA. Electronic address: flumepa@musc.edu","institution_ids":["https://openalex.org/I153297377"]},{"raw_affiliation_string":"MUSC Health Cystic Fibrosis Center, Medical University of South Carolina, 96 Jonathan Lucas St., Charleston, SC, USA","institution_ids":["https://openalex.org/I153297377"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056467598","display_name":"R. Scott Harris","orcid":"https://orcid.org/0000-0002-2684-6202","observed_orcids":["https://orcid.org/0000-0002-2684-6202"]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Scott Harris","raw_affiliation_strings":["Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, USA","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031110231","display_name":"Hildegarde Paz-D\u00edaz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hildegarde Paz-Diaz","raw_affiliation_strings":["Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, USA","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070886386","display_name":"Neil Ahluwalia","orcid":"https://orcid.org/0000-0001-6262-401X","observed_orcids":["https://orcid.org/0000-0001-6262-401X"]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neil Ahluwalia","raw_affiliation_strings":["Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, USA","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015284336","display_name":"Mark Higgins","orcid":"https://orcid.org/0009-0003-1260-6640","observed_orcids":["https://orcid.org/0009-0003-1260-6640"]},"institutions":[{"id":"https://openalex.org/I4210127480","display_name":"Vertex Pharmaceuticals (United Kingdom)","ror":"https://ror.org/03fs5jd74","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210127480","https://openalex.org/I61970326"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Mark Higgins","raw_affiliation_strings":["Vertex Pharmaceuticals (Europe) Limited, 2 Kingdom Street, London W2 6BD, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vertex Pharmaceuticals (Europe) Limited, 2 Kingdom Street, London W2 6BD, UK","institution_ids":["https://openalex.org/I4210127480"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038546781","display_name":"Daniel Campbell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Campbell","raw_affiliation_strings":["Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, USA","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080795365","display_name":"Indrias Berhane","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Indrias Berhane","raw_affiliation_strings":["Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, USA","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047391845","display_name":"Judy L. Shih","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I61970326","display_name":"Vertex Pharmaceuticals (United States)","ror":"https://ror.org/00anb1726","country_code":"US","type":"company","lineage":["https://openalex.org/I61970326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Judy L. Shih","raw_affiliation_strings":["Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA, USA","institution_ids":["https://openalex.org/I61970326"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086628162","display_name":"Gregory S. Sawicki","orcid":"https://orcid.org/0000-0003-3356-709X","observed_orcids":["https://orcid.org/0000-0003-3356-709X","https://orcid.org/0000-0002-5588-6297"]},"institutions":[{"id":"https://openalex.org/I1288882113","display_name":"Boston Children's Hospital","ror":"https://ror.org/00dvg7y05","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1288882113"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregory Sawicki","raw_affiliation_strings":["Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Boston, MA, USA","institution_ids":["https://openalex.org/I1288882113","https://openalex.org/I136199984"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5005915390"],"corresponding_institution_ids":["https://openalex.org/I153297377"],"apc_list":{"value":3700,"currency":"USD","value_usd":3700},"apc_paid":null,"fwci":1.1284,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.78736101,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":97},"biblio":{"volume":"22","issue":"3","first_page":"464","last_page":"470"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10665","display_name":"Cystic Fibrosis Research Advances","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10665","display_name":"Cystic Fibrosis Research Advances","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11651","display_name":"Inhalation and Respiratory Drug Delivery","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tezacaftor-ivacaftor","display_name":"tezacaftor/ivacaftor","score":0.9480000138282776},{"id":"https://openalex.org/keywords/cftr-modulator-therapy","display_name":"CFTR modulator therapy","score":0.8149999976158142},{"id":"https://openalex.org/keywords/long-term-safety","display_name":"long-term safety","score":0.9300000071525574},{"id":"https://openalex.org/keywords/lung-function","display_name":"lung function","score":0.7310000061988831},{"id":"https://openalex.org/keywords/fev1","display_name":"FEV1","score":0.8519999980926514},{"id":"https://openalex.org/keywords/pulmonary-exacerbations","display_name":"pulmonary exacerbations","score":0.9789999723434448},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7540000081062317},{"id":"https://openalex.org/keywords/liver-function","display_name":"liver function","score":0.652999997138977},{"id":"https://openalex.org/keywords/extend-trial","display_name":"EXTEND trial","score":0.8460000157356262},{"id":"https://openalex.org/keywords/open-label-extension","display_name":"open-label extension","score":0.871999979019165},{"id":"https://openalex.org/keywords/fixed-dose-combination","display_name":"fixed-dose combination","score":0.6389999985694885},{"id":"https://openalex.org/keywords/hemoptysis","display_name":"hemoptysis","score":0.5849999785423279},{"id":"https://openalex.org/keywords/nasopharyngitis","display_name":"nasopharyngitis","score":0.9300000071525574}],"concepts":[{"id":"https://openalex.org/C2776502428","wikidata":"https://www.wikidata.org/wiki/Q6095693","display_name":"Ivacaftor","level":4,"score":0.9284532070159912},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.90435791015625},{"id":"https://openalex.org/C2776938444","wikidata":"https://www.wikidata.org/wiki/Q178194","display_name":"Cystic fibrosis","level":2,"score":0.6380282044410706},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6103214621543884},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.5851789116859436},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5718733072280884},{"id":"https://openalex.org/C2777014857","wikidata":"https://www.wikidata.org/wiki/Q1383410","display_name":"Exacerbation","level":2,"score":0.5496453046798706},{"id":"https://openalex.org/C2776476923","wikidata":"https://www.wikidata.org/wiki/Q7725","display_name":"Evening","level":2,"score":0.43108946084976196},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3965594172477722},{"id":"https://openalex.org/C2778428886","wikidata":"https://www.wikidata.org/wiki/Q420470","display_name":"Cystic fibrosis transmembrane conductance regulator","level":3,"score":0.09997880458831787},{"id":"https://openalex.org/C1276947","wikidata":"https://www.wikidata.org/wiki/Q333","display_name":"Astronomy","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000627","descriptor_name":"Aminophenols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003550","descriptor_name":"Cystic Fibrosis","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":true},{"descriptor_ui":"D003550","descriptor_name":"Cystic Fibrosis","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003550","descriptor_name":"Cystic Fibrosis","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019005","descriptor_name":"Cystic Fibrosis Transmembrane Conductance Regulator","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D019005","descriptor_name":"Cystic Fibrosis Transmembrane Conductance Regulator","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D052117","descriptor_name":"Benzodioxoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D065101","descriptor_name":"Chloride Channel Agonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.jcf.2022.12.006","doi":"https://doi.org/10.1016/j.jcf.2022.12.006","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jcf.2022.12.006","pdf_url":null,"source":{"id":"https://openalex.org/S147774598","display_name":"Journal of Cystic Fibrosis","issn_l":"1569-1993","issn":["1569-1993","1873-5010"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Cystic Fibrosis","raw_type":"journal-article"},{"id":"pmid:36581484","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36581484","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":{"id":"doi:10.1016/j.jcf.2022.12.006","doi":"https://doi.org/10.1016/j.jcf.2022.12.006","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jcf.2022.12.006","pdf_url":null,"source":{"id":"https://openalex.org/S147774598","display_name":"Journal of Cystic Fibrosis","issn_l":"1569-1993","issn":["1569-1993","1873-5010"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Cystic Fibrosis","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320312517","display_name":"Vertex Pharmaceuticals","ror":"https://ror.org/00anb1726"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W1589654967","https://openalex.org/W2102496493","https://openalex.org/W2159746250","https://openalex.org/W2162070501","https://openalex.org/W2316431812","https://openalex.org/W2564673452","https://openalex.org/W2754849847","https://openalex.org/W2765825922","https://openalex.org/W2904538540","https://openalex.org/W2975850958","https://openalex.org/W2982296199","https://openalex.org/W3015162743","https://openalex.org/W3128973022","https://openalex.org/W4206217612"],"related_works":["https://openalex.org/W3014813780","https://openalex.org/W3128973022","https://openalex.org/W4388524266","https://openalex.org/W4409317760","https://openalex.org/W3089095538","https://openalex.org/W4212774905","https://openalex.org/W7136236822","https://openalex.org/W4410975638","https://openalex.org/W4375860631","https://openalex.org/W4250188752"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2023-01-06T00:00:00"}